Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
We send one confirmation email first. Only emails about NEOG, unsubscribe in one click. Privacy
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
NEOG holds $172M in cash and short-term investments (as of Aug 31, 2026) and its operations are currently cash-flow neutral or positive.
Dilution pressure: 0 · Low
Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when NEOG files for a raise →
| Holder | Type | Shares | % of shares | As of |
|---|---|---|---|---|
| Neuberger Berman Group LLC | Institution (13G, 5%+) | 16,570,795 | 7.59% | 2026-06-30 |
| Vanguard Portfolio Management | Institution (13G, 5%+) | 12,916,330 | 5.92% | 2026-03-31 |
| Vanguard Capital Management | Institution (13G, 5%+) | 11,164,628 | 5.11% | 2026-03-31 |
| James C Borel Director · +20,558 options |
Insider | 106,737 | 0.05% | 2026-10-29 |
| David H. Naemura Former CFO |
Insider | 90,388 | 0.04% | 2025-12-01 |
| Amy M Rocklin Former Chief Legal Officer |
Insider | 82,182 | 0.04% | 2026-05-18 |
| Richard Bryan Riggsbee CFO · +261,702 options |
Insider | 51,502 | 0.02% | 2026-08-14 |
| James P Tobin Director |
Insider | 43,347 | 0.02% | 2025-10-27 |
| Jeffrey D Capello Director · +20,558 options |
Insider | 42,892 | 0.02% | 2026-10-29 |
| Jennifer Evans Stacey Chief Legal Officer · +285,796 options |
Insider | 38,627 | 0.02% | 2026-08-14 |
| Aashima Gupta Director · +20,558 options |
Insider | 38,180 | 0.02% | 2026-10-29 |
| Gregory S Hastings VP, Animal Health |
Insider | 33,449 | 0.02% | 2026-10-29 |
Share count 218,306,034 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for NEOG and every other ticker you follow. Card required, cancel anytime.
Start 7-day free trial →